Commonly, the therapeutic effect of anti-PD-1/PD-L1 antibodies mainly depends on the PD-L1 expression status, such as tumor proportion score (TPS), combined positive score (CPS), and immune cell proportion score (IPS) (59). The gene discussed is PDCD1; the disease is neoplasm.